01—Abstract
Summary
Summary of the 10-Q filed April 25, 2024. Cited figures are marked; the original filing is the authoritative source.
DexCom, Inc. reported strong financial performance for the first quarter of 2024, with revenue increasing by 24% year-over-year to $921.0 milliona.
This growth was primarily driven by an increase in sales volume of their continuous glucose monitoring (CGM) systems, adding approximately 600,000 users to their global customer base in the prior year. The company also demonstrated significant profitability improvements, with operating income soaring by 114% and net income more than tripling to $146.4 millionb, resulting in a diluted EPS of $0.36. Operationally, DexCom continues to invest in research and development to enhance its product offerings and expand into new markets, including individuals with Type 2 diabetes not using insulin.
The company's balance sheet remains robust, with cash, cash equivalents, and marketable securities totaling $2.90 billionc at the end of the quarter, and positive operating cash flow of $209.2 million underscores its financial strength. However, investors should note ongoing patent litigation with Abbott, which, while currently assessed as not likely to result in a material adverse outcome, remains a point of ongoing legal scrutiny.
02—Key points
Key Highlights
- Revenue grew 24% year-over-year to $921.0 million, driven by increased sales volume and user base expansion.
- Net income significantly increased by 201% to $146.4 million, demonstrating strong profitability.
- Diluted Earnings Per Share (EPS) rose to $0.36, a substantial increase from $0.12 in the prior year period.
- Operating income surged by 114% to $101.1 million, indicating improved operational efficiency.
- The company generated robust operating cash flow of $209.2 million, up 35% year-over-year.
- Dexcom received FDA marketing clearance for its Stelo sensor, designed for individuals with Type 2 diabetes who do not use insulin, opening a new market segment.
- The company ended the quarter with a strong liquidity position, holding $2.90 billion in cash, cash equivalents, and short-term marketable securities.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2024, Dexcom Inc kept $0.16.
- Revenue$921.0M100.0%
- Cost of revenue−$359.1M39.0%
- Gross profit$561.9M61.0%
- Operating costs−$460.8M50.0%
- Operating income$101.1M11.0%
- Interest, other & tax$45.3M4.9%
- Net income$146.4M15.9%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed April 25, 2024Financial Statements
Q1 FY2024 against Q1 FY2023
| Line item | Q1 FY2024Q1 FY2023 | Change |
|---|---|---|
| Revenue | $921.00M$741.50M | +24.2% |
| Cost of Revenue | $359.10M$278.90M | +28.8% |
| Gross Profit | $561.90M$462.60M | +21.5% |
| R&D Expenses | $141.50M$119.00M | +18.9% |
| SG&A Expenses | $319.30M$296.40M | +7.7% |
| Operating Expenses | $460.80M$415.40M | +10.9% |
| Operating Income | $101.10M$47.20M | +114.2% |
| Interest Expense | $3.70M$3.70M | 0.0% |
| Net Income | $146.40M$48.60M | +201.2% |
| EPS (Basic) | $0.38$0.13 | +192.3% |
| EPS (Diluted) | $0.36$0.12 | +200.0% |
| Shares Outstanding (Basic) | 390.20M386.70M | +0.9% |
| Shares Outstanding (Diluted) | 416.70M418.50M | −0.4% |
05—Questions
Frequently Asked Questions
What was the primary driver of Dexcom's revenue growth in Q1 2024?
The primary driver of Dexcom's revenue growth in the first quarter of 2024 was the increased sales volume of their disposable continuous glucose monitoring (CGM) sensors, attributed to the continued expansion of their worldwide customer base. The company added approximately 600,000 users in the preceding year.
How did Dexcom's profitability change in the first quarter of 2024?
Dexcom experienced significant improvements in profitability. Net income more than tripled, increasing by 201% to $146.4 million, while operating income saw a substantial jump of 114% to $101.1 million. This was also reflected in the diluted EPS, which grew to $0.36 from $0.12 in the prior year quarter.
What is the status of the patent litigation with Abbott?
Dexcom and Abbott are involved in ongoing patent infringement litigation. In a recent trial regarding Dexcom's G6 system, a jury found infringement on one patent, but also found non-infringement on two others and invalidated a third. The jury did not award damages for the one patent found to be infringed, and Dexcom plans to challenge this finding. The company believes it is not probable that they will have an unfavorable outcome leading to a material loss, and has not recorded an accrual for a contingent liability at this time, but notes ongoing uncertainty in various international jurisdictions.
What new product or market expansion did Dexcom announce?
Dexcom received FDA marketing clearance for its new Stelo sensor in March 2024. This 15-day sensor is specifically designed for people with Type 2 diabetes who do not use insulin and is notable for being the first glucose biosensor that does not require a prescription. This marks an expansion into a new customer segment for the company.
06—Continue